Business Roundtable
Finance/Regulatory: Sarbanes-Oxley Blues - Impact of Section 404 and Prescription for Reform
Tuesday, February 14, 2006
4:00 PM
Conrad Suite
CEO and investors will examine the disproportionate costs and unintended consequences of section 404 compliance for smaller public companies and examine the opportunities for reform by the SEC.
Moderators
- Edmund M. Ruffin; Vice President for Business Development & Emerging Companies, Biotechnology Industry Organization (BIO)
Panelists
- Rick Brounstein; Chief Financial Officer, Calypte Biomedical Corporation
- Boyd Clarke; Chief Executive Officer, Neose
- Gary Lessing; Executive Vice President and CFO, Avalon Pharmaceuticals